Revolution Medicines, Inc. (RVMD)

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?...

American Century Companies Inc. reduced its holdings in Revolution Medicines, Inc. (NASDAQ: RVMD) by 38.7% in the undefined quarter, according to the company in its most recent filing with the SEC. Th...

AXQ Capital LP bought a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and E...

Revolution Medicines, Inc. ( RVMD ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participan...

Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conf...

RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data....

Nisa Investment Advisors LLC cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 38.0% during the second quarter, according to the company in its most recent disclosure with the...

Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Cha...

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has i...

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...